{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T18:10:03Z","timestamp":1739124603675,"version":"3.37.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ejca.2009.04.032","type":"journal-article","created":{"date-parts":[[2009,5,23]],"date-time":"2009-05-23T08:45:12Z","timestamp":1243068312000},"page":"1904-1908","source":"Crossref","is-referenced-by-count":4,"title":["R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9"],"prefix":"10.1016","volume":"45","author":[{"given":"Wei Peng","family":"Yong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir D.","family":"Undevia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Innocenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Ratain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2009.04.032_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1006174622061","article-title":"Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate","volume":"16","author":"Corbett","year":"1998","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.ejca.2009.04.032_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1023\/A:1006206814025","article-title":"Preclinical antitumor activity of XK469 (NSC 656889)","volume":"16","author":"LoRusso","year":"1998","journal-title":"Invest New Drugs"},{"issue":"21","key":"10.1016\/j.ejca.2009.04.032_bib3","doi-asserted-by":"crossref","first-page":"12168","DOI":"10.1073\/pnas.96.21.12168","article-title":"XK469, a selective topoisomerase IIbeta poison","volume":"96","author":"Gao","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.ejca.2009.04.032_bib4","first-page":"3336","article-title":"The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways","volume":"7","author":"Ding","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2009.04.032_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0304-3835(01)00518-3","article-title":"Pro-apoptotic interactions between XK469 and the peripheral benzodiazepine receptor","volume":"168","author":"Kessel","year":"2001","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.ejca.2009.04.032_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.1570","article-title":"Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination","volume":"97","author":"Lin","year":"2002","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2009.04.032_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-002-0425-7","article-title":"XK469, a novel antitumor agent, inhibits signaling by the MEK\/MAPK signaling pathway","volume":"49","author":"Lin","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.ejca.2009.04.032_bib8","first-page":"5794","article-title":"Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom\u2019s macroglobulinemia xenograft model","volume":"9","author":"Mensah-Osman","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2009.04.032_bib9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1006\/bbrc.2001.4249","article-title":"Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I","volume":"280","author":"Snapka","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.ejca.2009.04.032_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00280-004-0962-3","article-title":"Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug\u2013drug interactions","volume":"56","author":"Anderson","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2009.04.032_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0006-2952(99)00167-7","article-title":"Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways","volume":"58","author":"Bort","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2009.04.032_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0006-2952(97)00143-3","article-title":"Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C","volume":"54","author":"Hamman","year":"1997","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2009.04.032_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1160\/TH03-05-0325","article-title":"Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype","volume":"91","author":"van Dijk","year":"2004","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.ejca.2009.04.032_bib14","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.ejca.2008.05.018","article-title":"A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours","volume":"44","author":"Undevia","year":"2008","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2009.04.032_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.1987.tb03074.x","article-title":"The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites","volume":"23","author":"Purba","year":"1987","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2009.04.032_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.ejca.2009.04.032_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1124\/dmd.30.3.344","article-title":"Chiral pharmacokinetics and inversion of enantiomers of a new quinoxaline topoisomerase IIbeta poison in the rat","volume":"30","author":"Zheng","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.ejca.2009.04.032_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-9556(25)07368-4","article-title":"Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies","volume":"24","author":"Kunze","year":"1996","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909003281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909003281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T17:40:10Z","timestamp":1739122810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909003281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0959804909003281"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.04.032","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}